Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324857543> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2324857543 endingPage "838" @default.
- W2324857543 startingPage "833" @default.
- W2324857543 abstract "The prognosis for advanced esophageal carcinoma is poor with a median survival of 9-12 months and 5-year-survival rate of 10-20%. Combination chemotherapy with cisplatin and 5-fluorouracil (5-FU) is considered to be the standard therapy, but has a high potential of side effects and is usually not given on an ambulatory basis. This phase I study was designed to find the maximum tolerated dose (MTD) of weekly cisplatin in combination with standard doses of gemcitabine (1,000 mg/m(2), 30 min) and 5-FU (750 mg/m(2), 24 h)/folinic acid (200 mg/m(2), 30 min). All drugs were to be given on a day 1, 8, 15 and 22 of a 6-weekly cycle in an outpatient setting. Nineteen chemonaive patients with inoperable stage IIa, III and IV squamous cell carcinoma and adenocarcinoma of the esophagus were enrolled into the study. Eight, six and five patients were enrolled at cisplatin dose levels 0 (20 mg/m(2) ), I (25 mg/m(2) ) and II (30 mg/m(2)), respectively. One hundred and eighty-one out of 187 treatments (55 cycles) were given on an outpatient basis. The dose-limiting toxicities of this schedule were leukopenia and thrombocytopenia. Other side effects were mild. Dose level II (30 mg/m(2)) was defined as the MTD for cisplatin when used in this combination and schedule. Partial responses were observed in 10 of the 19 enrolled patients. The side effect profile seen in this study in combination with the preliminary evidence of efficacy justifies further testing in a phase II setting with a cisplatin dose of 25 mg/m(2) and offers a treatment option for patients in an outpatient setting." @default.
- W2324857543 created "2016-06-24" @default.
- W2324857543 creator A5015232096 @default.
- W2324857543 creator A5015917994 @default.
- W2324857543 creator A5017710000 @default.
- W2324857543 creator A5018926438 @default.
- W2324857543 creator A5024665791 @default.
- W2324857543 creator A5031533961 @default.
- W2324857543 creator A5067314177 @default.
- W2324857543 date "2002-09-01" @default.
- W2324857543 modified "2023-10-01" @default.
- W2324857543 title "Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer" @default.
- W2324857543 cites W1904805820 @default.
- W2324857543 cites W1920900131 @default.
- W2324857543 cites W1972245712 @default.
- W2324857543 cites W1988443167 @default.
- W2324857543 cites W2014564927 @default.
- W2324857543 cites W2029515374 @default.
- W2324857543 cites W2032792368 @default.
- W2324857543 cites W2040143851 @default.
- W2324857543 cites W2106712902 @default.
- W2324857543 cites W2117476647 @default.
- W2324857543 cites W2120518038 @default.
- W2324857543 cites W2125406417 @default.
- W2324857543 cites W2223406810 @default.
- W2324857543 doi "https://doi.org/10.1097/00001813-200209000-00008" @default.
- W2324857543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12394268" @default.
- W2324857543 hasPublicationYear "2002" @default.
- W2324857543 type Work @default.
- W2324857543 sameAs 2324857543 @default.
- W2324857543 citedByCount "8" @default.
- W2324857543 countsByYear W23248575432014 @default.
- W2324857543 countsByYear W23248575432022 @default.
- W2324857543 crossrefType "journal-article" @default.
- W2324857543 hasAuthorship W2324857543A5015232096 @default.
- W2324857543 hasAuthorship W2324857543A5015917994 @default.
- W2324857543 hasAuthorship W2324857543A5017710000 @default.
- W2324857543 hasAuthorship W2324857543A5018926438 @default.
- W2324857543 hasAuthorship W2324857543A5024665791 @default.
- W2324857543 hasAuthorship W2324857543A5031533961 @default.
- W2324857543 hasAuthorship W2324857543A5067314177 @default.
- W2324857543 hasConcept C121608353 @default.
- W2324857543 hasConcept C126322002 @default.
- W2324857543 hasConcept C2776694085 @default.
- W2324857543 hasConcept C2778239845 @default.
- W2324857543 hasConcept C2779742542 @default.
- W2324857543 hasConcept C2779804826 @default.
- W2324857543 hasConcept C2780258809 @default.
- W2324857543 hasConcept C2780456651 @default.
- W2324857543 hasConcept C2780873365 @default.
- W2324857543 hasConcept C3019864225 @default.
- W2324857543 hasConcept C31760486 @default.
- W2324857543 hasConcept C35785553 @default.
- W2324857543 hasConcept C71924100 @default.
- W2324857543 hasConcept C90924648 @default.
- W2324857543 hasConceptScore W2324857543C121608353 @default.
- W2324857543 hasConceptScore W2324857543C126322002 @default.
- W2324857543 hasConceptScore W2324857543C2776694085 @default.
- W2324857543 hasConceptScore W2324857543C2778239845 @default.
- W2324857543 hasConceptScore W2324857543C2779742542 @default.
- W2324857543 hasConceptScore W2324857543C2779804826 @default.
- W2324857543 hasConceptScore W2324857543C2780258809 @default.
- W2324857543 hasConceptScore W2324857543C2780456651 @default.
- W2324857543 hasConceptScore W2324857543C2780873365 @default.
- W2324857543 hasConceptScore W2324857543C3019864225 @default.
- W2324857543 hasConceptScore W2324857543C31760486 @default.
- W2324857543 hasConceptScore W2324857543C35785553 @default.
- W2324857543 hasConceptScore W2324857543C71924100 @default.
- W2324857543 hasConceptScore W2324857543C90924648 @default.
- W2324857543 hasIssue "8" @default.
- W2324857543 hasLocation W23248575431 @default.
- W2324857543 hasLocation W23248575432 @default.
- W2324857543 hasOpenAccess W2324857543 @default.
- W2324857543 hasPrimaryLocation W23248575431 @default.
- W2324857543 hasRelatedWork W2282258681 @default.
- W2324857543 hasRelatedWork W2324857543 @default.
- W2324857543 hasRelatedWork W2347428207 @default.
- W2324857543 hasRelatedWork W2356099210 @default.
- W2324857543 hasRelatedWork W2361287035 @default.
- W2324857543 hasRelatedWork W2369781240 @default.
- W2324857543 hasRelatedWork W2388948256 @default.
- W2324857543 hasRelatedWork W2394853503 @default.
- W2324857543 hasRelatedWork W2604113606 @default.
- W2324857543 hasRelatedWork W1980133017 @default.
- W2324857543 hasVolume "13" @default.
- W2324857543 isParatext "false" @default.
- W2324857543 isRetracted "false" @default.
- W2324857543 magId "2324857543" @default.
- W2324857543 workType "article" @default.